Immunoregulatory defects in patients with systemic lupus erythematosus in clinical remission
Open Access
- 1 May 2003
- journal article
- research article
- Published by SAGE Publications in Lupus
- Vol. 12 (5) , 386-393
Abstract
Little is known about the immune system of patients with systemic lupus erythematosus(SLE) during periods of silent disease. To address this issue we analysed lymphoid populations and cytokine productionof mononuclearcells obtained from SLE patients in remission.We studied 43 patients with inactive disease, 10 with active disease and 30 controls. Remission was defined as at least 1 year during which lack of clinical disease activity permitted withdrawal of all treatment. Remission length ranged from 1 to 30 years. Flow cytometry and ELISA were used to study lymphoid populations (CD4, CD8 and CD19) and cytokineproduction(IL-2, 4, 10, 12 and 18). Patientswith short remission periods (up to 15 years) exhibited an increased percentage of B cells; production of IL-2, IL-10 and IL-12 was decreased;productionof IL-18 was increased. Interestingly, patients from groups with long time of inactive disease had corrected most alterations, but had an impaired IL-18 expression. IL-12 production correlated strongly with the length of the remission period (r 0.7565). The immune system of patients with inactive lupus has partially corrected the disturbances present during disease activity.This is accomplishedgradually, sometimes until counter-regulatoryalterationsare developed. This may allow patients to remain without disease activity.Keywords
This publication has 19 references indexed in Scilit:
- Cytokines and systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2000
- Dysregulation of interleukin‐10 production in relatives of patients with systemic lupus erythematosusArthritis & Rheumatism, 1997
- In vitro apoptosis and expression of apoptosis‐related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseasesArthritis & Rheumatism, 1997
- Lymphocytes, cytokines, inflammation, and immune traffickingCurrent Opinion in Rheumatology, 1996
- In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: lack of relationship with clinical disease activityLupus, 1996
- Remission of Systemic Lupus ErythematosusMedicine, 1996
- Cytokine abnormalities in human lupusClinical Immunology and Immunopathology, 1992
- Familial Occurrence of impaired interleukin-2 activity and increased peripheral blood B cells actively secreting immunoglobulins in systemic lupus erythematosusThe American Journal of Medicine, 1989
- T-cell subpopulations in the peripheral blood of patients with connective tissue diseases as determinated by flow cytometry using monoclonal antibodiesClinical Immunology and Immunopathology, 1983
- Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus.Journal of Clinical Investigation, 1982